FDA
-
-
-
-
-
-
-
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
-
-
-
-
-
-
-
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
-
-
-
-
-
-
-
Mesoblast Participation at Piper Sandler Conference
-
-
-
-
-
-
-
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
-
-
-
-
-
-
-
Mesoblast Limited (MSB) received seven years of orphan-drug exclusive approval from US FDA
-
-
-
-
-
-
-
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
-
-
-
-
-
-
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
-
324,417 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

